Canada markets closed

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
3.4650+0.0350 (+1.02%)
At close: 04:00PM EDT
3.4700 +0.01 (+0.14%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.4300
Open3.4300
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.4201 - 3.5800
52 Week Range2.9300 - 5.0500
Volume5,541
Avg. Volume35,332
Market Cap187.576M
Beta (5Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-2.6300
Earnings DateMay 21, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

    The first abstract demonstrates that the improvements of MACK-3, a diagnostic test for metabolic dysfunction-associated steatohepatitis, parallel the histological response to lanifibranor therapy in patients with MASH/NASH, in the NATIVE Phase IIb clinical trial.The second abstract brings additional evidence supporting the role of intrahepatic vascular alterations in the development of MASLD-related portal hypertension and the progression to MASH and highlights the potential of lanifibranor in a

  • GlobeNewswire

    Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

    Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 2024, compared to €26.9 million, €0.01 million and €9.0 million as of December 31, 2023, respectively.The fourth scheduled DMC meeting recommended to continue the NATiV3 Phase III clinical trial without modification of the current protocol, based on the pre-planned review of interim safety data of more than 900 patients randomized in the main and exploratory co

  • GlobeNewswire

    Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

    The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who experienced the adverse event of increased liver test re